hotspot -WSS

hotspot

author：fashion 2025-09-27 23:03:48 - browse：25358

Vertex Pharmaceuticals Inc. building — Craig F. Walker/The Boston Globe

Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease.

The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

“The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Lab trade group sues FDA to halt regulation of lab

explore

WSS

Childbirth

Fed up with FDA, ALS advocates consider a take

Adam's Biotech Scorecard: Do Sarepta's exon

Adam's Biotech Scorecard: Do Sarepta's exon

Neurocrine congenital adrenal hyperplasia trial succeeds

Chamber of Commerce, DOJ clash in court over drug prices

hotspot

hotspot

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Stigma and the return of syphilis

In Memoriam: Notable people who died in 2023

Startling documents reveal new facets of Sacklers' opioid empire

Bright Health sells Medicare Advantage business to Molina

What happened to the House vote on health price transparency?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Biohaven protein

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

House panel takes first step toward fixing drug shortages

hotspot

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

PBMs drew scrutiny in House hearing — and so did pharma

The unintended consequences of overturning Roe v. Wade

Neurocrine congenital adrenal hyperplasia trial succeeds

FDA weighs limits of animal data in assessing artificial wombs

How the messy conversation about Dolly changed bioethics

focus

leisure time

explore

knowledge